Latest news with #Revance
Globe and Mail
09-04-2025
- Business
- Globe and Mail
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco
Redefining Skin Biome Care with BIOJUVE NASHVILLE, Tenn. , /CNW/ -- Revance is proud to announce that BIOJUVE, the innovative skin biome care product from Crown Aesthetics, has been awarded the prestigious Best Cosmetics of the Year at the 12th Annual Aesthetic & Anti-Aging Medicine World Congress (AMWC), in Monaco , Montecarlo. The ceremony, which took place on March 27th at the Grimaldi Forum in Monaco , recognized excellence in aesthetics. BIOJUVE stood out among a competitive field of highly respected nominees. This accolade underscores BIOJUVE's commitment to advancing skin health through its unique approach to skin biome care. "We are incredibly honored that BIOJUVE has been recognized as the Best Cosmetics of the Year," said Jeff Bedard , Founder and CEO. "This award is a testament to our commitment to innovation and excellence in skin biome care. At Revance, we strive to develop cutting-edge solutions that redefine skincare, and BIOJUVE represents a breakthrough in harnessing the power of the skin's microbiome for healthier, more radiant skin. We are excited to continue leading the industry with science-backed, transformative products." The AMWC Awards celebrate physicians for excellence in clinical practice and recognize industry leaders for product and device development innovations within the aesthetics field. Winning this award highlights BIOJUVE and its significant impact on the industry and Revance's dedication to providing cutting-edge solutions for skin health. For more information about the age-defying power of a true skin probiotic with BIOJUVE, please visit About Revance Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.
Associated Press
02-03-2025
- Business
- Associated Press
RVNC Deadline: RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, March 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the 'Class Period'), of the important March 4, 2025 lead plaintiff deadline. So what: If you purchased Revance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Revance class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 4, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Revance was in material breach of the Distribution Agreement with Teoxane SA; (2) the foregoing subjected Revance to an increased risk of litigation, as well as monetary and reputational harm; (3) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended; and (4) Neutron's only contract was made at a discount with an unreliable partner; and (5) as a result, Revance's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Revance class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060
Associated Press
01-03-2025
- Business
- Associated Press
SHAREHOLDER ALERT: Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 Laurence D. King 1999 Harrison Street, Suite 1560 Oakland, California 94612
Associated Press
25-02-2025
- Business
- Associated Press
Securities Class Action Lawsuit Against Revance Therapeutics, Inc. (RVNC) - Contact Kaplan Fox Before Deadline on March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King 1999 Harrison Street, Suite 1560 Oakland, California 94612
Associated Press
13-02-2025
- Business
- Associated Press
Kaplan Fox Alerts Revance Therapeutics Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ('Revance' or the 'Company') (NASDAQ: RVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the 'Class Period'). If you are an investor in Revance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than March 4, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. Revance is a biotechnology company and the distributor of certain dermal filler products pursuant to an exclusive distribution agreement with Teoxane SA. On August 12, 2024, Revance issued a press release announcing that the Company had entered into a merger agreement with Crown Laboratories ('Crown'). Under the terms of the agreement, the press release indicated that Crown would commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share (the 'Tender Offer'). Then, on September 23, 2024, Revance disclosed that it 'received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA.' Due to the dispute with Teoxane, the Company advised that Crown's Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance stock fell $.445 per share, or 7.66%, to close at $5.365 per share on September 23, 2024. Then, on December 9, 2024, the Company disclosed that Crown and Revance had amended their merger agreement, and that Crown would commence a tender offer on December 12, 2024 to acquire all outstanding shares of Revance common stock for $3.10 per share, more than 50% lower than the original purchase price. On this news, the price of Revance stock fell $.79 per share, or 20.68%, to close at $3.03 per share on December 9, 2024. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (i) Revance was in material breach of the Distribution Agreement; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (iii) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 1999 Harrison Street, Suite 1560 Oakland, California 94612
